vericiguat (Verquvo)
Jump to navigation
Jump to search
Indications
- adjunctive treatment for left ventricular systolic dysfunction in patients with either recent heart failure hospitalization or intravenous diuretic therapy[1][4]
- benefit for patients with worsening heart failure (NNT=37)[5]
Contraindications
- of no benifit for treatment of left ventricular diastolic dysfunction[2]
Dosage
Adverse effects
Mechanism of action
- soluble guanylate cyclase stimulator
- enhances intracellular cyclic GMP pathway
More general terms
References
- ↑ 1.0 1.1 Armstrong PW. Pieske N, Anstrom KJ et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020; 382:1883-1893. Mar 28; [e-pub]. PMID: https://pubmed.ncbi.nlm.nih.gov/32222134 https://www.nejm.org/doi/10.1056/NEJMoa1915928
Butler J, Anstrom KJ Armstrong PW Comparing the benefit of novel therapies across clinical trials: Insights from the VICTORIA trial. Circulation 2020 Mar 28; [e-pub] PMID: https://pubmed.ncbi.nlm.nih.gov/32223438 https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.047086 - ↑ 2.0 2.1 Armstrong PW et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1512. PMID: https://pubmed.ncbi.nlm.nih.gov/33079152 https://jamanetwork.com/journals/jama/article-abstract/2771900
- ↑ FDA Approvals, Highlights, and Summaries: Family Medicine Medscape - Feb 17, 2022 https://reference.medscape.com/viewarticle/967605
- ↑ 4.0 4.1 Medical Knowledge Self Assessment Program (MKSAP) 20 American College of Physicians, Philadelphia 2025
- ↑ 5.0 5.1 Butler J et al. Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2025 Sep 27; 406:1341. PMID: https://pubmed.ncbi.nlm.nih.gov/40897189 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01665-4/abstract
Zannad F et al. Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: An individual participant data analysis of the VICTORIA and VICTOR trials. Lancet 2025 Sep 27; 406:1351. PMID: https://pubmed.ncbi.nlm.nih.gov/40897188 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01682-4/fulltext
Kohsaka S et al. Vericiguat across the heart failure spectrum. Lancet 2025 Sep 27; 406:1314. PMID: https://pubmed.ncbi.nlm.nih.gov/40897191